Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

Pages

8063 items
10:57 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Vertex gets reimbursement deal for Orkambi in Sweden

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said June 18 it agreed to a long-term access agreement for cystic fibrosis drug Orkambi lumacaftor/ivacaftor with Swedish authorities. Beginning July 1, Orkambi will be reimbursed in Sweden at an undisclosed...
10:56 AM, Jun 22, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE recommends Roche's Ocrevus for relapse-remitting multiple sclerosis

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat relapse-remitting multiple sclerosis. In January, the European Commission approved the second-generation humanized mAb against CD20...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER panel says long-term value for Aimovig for migraines is intermediate

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER offers policy recommendations in final report for cystic fibrosis drugs

ICER released its final evidence report June 7 on CF transmembrane conductance regulator (CFTR) therapies that found that while Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Symdeko tezacaftor/ivacaftor offered a net benefit compared with supportive care alone,...
9:20 AM, Jun 15, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Zejula included on CDF

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Zejula niraparib from Tesaro Inc. (NASDAQ:TSRO) within the country's Cancer Drugs Fund (CDF) to treat relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian...
8:14 AM, Jun 08, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE recommends Keytruda in first-line NSCLC

Merck & Co. Inc. (NYSE:MRK) said U.K.'s NICE issued final guidance recommending Keytruda pembrolizumab be routinely available to treat non-small cell lung cancer. The PD-1 inhibitor is the first immunotherapy to show cost-effectiveness and be...
4:11 PM, Jun 07, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses...
12:23 PM, Jun 01, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Vertex, NHS have second meeting for CF medicines

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it had a second meeting with NHS England on May 25 to discuss access to Vertex's cystic fibrosis medicines. The company said there "is still some way to go to...
11:18 AM, May 25, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE does not recommend Chiesi's Lamzede for alpha-mannosidosis

U.K.’s NICE recommended against the use of Lamzede velmanase alfa from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat alpha-mannosidosis, an ultra-Orphan disease that affects about 25 people in England. The European Commission approved the recombinant form...
7:51 AM, May 25, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

FoundationOne CDx secures nine-month CMS reimbursement

Foundation Medicine Inc. (NASDAQ:FMI) said CMS approved the status of FoundationOne CDx as a new Advanced Diagnostic Laboratory Test (ADLT). During a nine-month period that begins July 1, the biotech will collect and assess private payer...

Pages